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ABSTRACT
Herpes simplex encephalitis (HSE) is the most
common single cause of viral encephalitis in
infants and children. Treated or untreated, it
can be associated with considerable morbidity
and mortality, and its presentation is usually
insidious and non-specific. Prompt and careful
investigation is important in order to establish
the diagnosis so that treatment can be
optimised. We address some common
questions arising when diagnosing
and treating presumed HSE throughout
childhood.
Composite case vignette: a 9-month-old girl with herpes simplex encephalitis
A previously well 9-month-old girl presented with fever and a 40 min focal seizure. She was started
on intravenous ceftriaxone and aciclovir, intubated and ventilated. An MRI brain scan on day 1
demonstrated features consistent with focal encephalitis with left frontotemporal lobe involvement.
After stabilisation, lumbar puncture was performed. One week later, the PCR result confirmed
herpes simplex type 1 infection. She completed 3 weeks of intravenous aciclovir via a peripherally
inserted central catheter line at a dose of 500 mg/m2 three times daily. Repeat MRI brain scanning
on day 14 showed extensive destruction of the left hemisphere.
After completion of the treatment course, she was commenced on 3 months of oral antiviral
prophylaxis. Two months after completing this, she suddenly became encephalitic with behav-
ioural change and choreoathetoid movements. She had facial dyskinesia and numerous non-
purposeful movements, but no fever. Intravenous aciclovir was restarted at 500 mg/m2 TDS, and
this was continued for 21 days although no herpes simplex virus (HSV) was subsequently
detected by PCR in the cerebrospinal fluid (CSF). Further investigations revealed that the patient
had developed autoantibodies to a neurotransmitter receptor. She remains severely disabled,
requires feeding via gastrostomy tube and requires 24 h care.
Composite case vignette 2: neonatal herpes simplex encephalitis
A term baby presented on day 15 of life with poor feeding, fever and lethargy. His transaminases
were raised and there was disseminated intravascular coagulation. High-dose intravenous cefotaxime
and intravenous aciclovir (20 mg/m2 TDS) were initiated immediately. Despite fresh frozen plasma and
vitamin K, a lumbar puncture (LP) was deemed unsafe for several days. HSV type 2 was detected on
blood PCR. A brain MRI scan on day 2 was normal. On day 21 of intravenous aciclovir, the baby had
a ‘proof of cure’ LP and a repeat MRI. The latter was now abnormal, with several punctate haemor-
rhagic foci within the deep cerebral white matter. The CSF PCR was positive for HSV-2. Intravenous
aciclovir was finally ceased after a negative HSV PCR result at week 6. The baby was prescribed oral
aciclovir prophylaxis until the age of 15 months. Three months after discontinuing prophylaxis, he had
a further episode of herpes encephalitis. Oral antiviral prophylaxis was recommenced for a further
3 year . At age 5 years, he is neurocognitively normal and doing well at primary school.
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WHAT ARE THE PRESENTING FEATURES OF
NEONATAL AND CHILDHOOD HERPES SIMPLEX
ENCEPHALITIS?
Herpes simplex encephalitis (HSE) is a devastating
disease that can be difficult to diagnose in its early stages.
By definition, neonatal herpes simplex (HSV) disease pre-
sents in the first 4 weeks of life and is almost always
acquired by perinatal exposure to HSV. Illness symptoms
often begin between the first 7–21 days of life. There is a
spectrum of clinical syndromes; encephalitis is the most
serious presentation, usually associated with lethargy,
fever and convulsions. Identifying the source of HSE in
neonatal disease can be difficult as a history of known
maternal HSV disease (genital or occasionally oral) is not
universal and maternal disease may be asymptomatic.
Childhood HSE presents with similar features: fever,
altered mental state (encephalopathy), a deteriorating
level of consciousness, focal seizures or focal neurological
abnormalities. The infective source is usually elusive.
Parents can describe encephalopathy as a change in behav-
iour, sleepiness or confusion. Children with normal
behaviour at presentation may become confused later as
the encephalitis progresses.
DOES A CHILD WITH HSE HAVE TO HAVE
EXTERNAL LESIONS FOR THE DIAGNOSIS TO BE
LIKELY?
In neonates, skin lesions may be present. However,
they may appear later in the clinical course than the
presenting fever, lethargy or even seizures. In child-
hood HSE, only 10% have a prior history of mucosal
symptoms such as cold sores or conjunctivitis.1
Therefore, diagnosis requires a high index of
suspicion.
HOW COMMON IS HSE?
Neonatal disease is more common than childhood
disease. The incidence of severe disease in infants is 1
in 64 000 infants per year. In children over 1 year,
HSE is nearly four times less common, occurring in 1
in 230 000 children per year.2
HOW DO I MANAGE HSE?
Start antivirals urgently when HSE is suspected—
earlier treatment is associated with a better outcome.
Assess the child carefully for seizure activity, which
may be subtle, and treat this promptly in order to
avoid further increases in intracranial pressure.
Involve the intensive care team early as infants and
children with HSE can deteriorate quickly. Ensure
adequate hydration as high-dose aciclovir can cause
acute renal failure.
SHOULD A LUMBAR PUNCTURE ALWAYS BE
ATTEMPTED IN HSE?
CSF testing is an essential component of the diagnos-
tic work-up; see box 1 for CSF investigations in chil-
dren with suspected encephalitis. CSF should be
tested as soon as it is safe to perform an LP in any
child with suspected encephalitis. CSF can show lym-
phocytes or neutrophils.
It is common that insufficient CSF is obtained and
it is important to take enough for local laboratory
requirements. Children produce approximately
0.35 mL/kg of CSF per hour, and it is safe to take up
to 0.2 mL/kg CSF, typically 1.5–2 mL (60 drops) from
a 10 kg child and more from older children.3
DOES IT MAKE A DIFFERENCE IF THE PCR
IS POSITIVE FOR HSV-1 OR FOR HSV-2?
No, not really. HSV-1 is more common in childhood
HSE. HSV-2 tends to be associated with genital
herpes and is more common in neonatal HSE.
Although neonatal disease is often more severe than
childhood HSE, the HSV type does not dictate this
and devastating HSE disease can occur in both age
ranges.
WHAT IS THE BEST NEUROIMAGING MODALITY?
Children presenting with an altered mental state and a
fever may have a CT scan, preferably with contrast, to
look for space-occupying lesions—tumours, abscesses
or haematomas. However, MRI is better than CT for
the diagnosis of encephalitis, so at least one brain
MRI scan should be performed during the acute clin-
ical course. A normal MRI does not rule out HSE,
particularly early in the course of the disease, so it
should be repeated after 4–7 days if suspicion
remains. This information will contribute to diagnos-
tic certainty and aid decision making about stopping
or continuing the acute antiviral treatment course.
Box 1 Cerebrospinal fluid investigations for the
initial investigation of encephalitis4
▸ If possible, measure the opening pressure with mano-
metry. A raised pressure indicates that a meningo/
encephalitic process is likely.
▸ Microscopy, culture and sensitivity analysis for
bacteria.
▸ A broad first-line virus screen in encephalitis would
include PCR for herpes simplex virus (HSV)-1 and
HSV-2, VZV, enterovirus, parechovirus, EBV, HHV6,
mumps. The differential is wider in children with
impaired immunity.
▸ A biochemistry sample for glucose (with paired
blood), lactate and protein.
▸ Additional sample should be saved for further
testing–such as antibodies or oligoclonal bands (with
paired serum sample).
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IS AN EEG REQUIRED?
Even after LP and MRI, there can be diagnostic uncer-
tainty about HSE, and an EEG may provide additional
diagnostic clues. The typical pattern is of periodic
lateralising epileptiform discharges in the temporal
lobe, with slow wave complexes occurring at intervals
of 2–3 s. While these are strongly associated with
HSE, they can be seen in other disorders including
space-occupying lesions, so the triad of investigations
—CSF analysis, MRI and EEG—are the diagnostic
gold standard.
WHAT THERAPY IS RECOMMENDED WHILE
WAITING FOR THE INVESTIGATION RESULTS?
There is considerable clinical overlap between patients
with encephalitis, meningitis and septic shock.
Therefore, patients are usually prescribed broad-
spectrum antibiotics and high-dose aciclovir until test
results are available. Because of the severity and the
non-specific presentation of neonatal disease, some
clinicians start aciclovir in all neonates less than
21 days of age in whom antibiotic therapy is being
given empirically for suspected sepsis,5 although
others have cautioned that aciclovir is inappropriately
or excessively used in children of all ages.6
WHAT IS ADEQUATE TREATMENT?
High-dose intravenous aciclovir is most effective when
started early. Following disease relapses in early aciclo-
vir studies in neonates, the standard of care became
high-dose intravenous aciclovir given for 21 days for
neonatal HSE.7 However, there are no published ran-
domised controlled trials (RCTs) on dosing or dur-
ation for HSE treatment of older children. Table 1
gives an overview of HSE treatment. Maintaining
intravenous access for the required duration of the aci-
clovir course can be problematic, so early insertion of
a PICC line once the diagnosis is strongly suspected
or confirmed can be very helpful. Repeating an LP at
the end of 21 days of treatment to ensure a negative
CSF PCR result is associated with a better outcome,8
but this is not universal practice. Centres that advocate
a ‘proof of cure’ LP recommend continuing intraven-
ous antiviral therapy where the day 21 CSF remains
HSV PCR positive, especially in neonatal disease.8
There is no place for oral aciclovir or valaciclovir in
the treatment of acute HSE given the potential disease
severity. Nor is there any evidence to support steroid
use in childhood HSE.
IS ACICLOVIR RESISTANCE AN ISSUE?
In immunocompetent patients, viral resistance to aci-
clovir occurs rarely and is not clinically significant, the
reported prevalence being less than 1%.12 However,
in immunocompromised patients, this figure rises to
6%. The degree of immunosuppression, duration and
frequency of exposure to aciclovir appear to be the
most important risk factors for resistance. Resistance
testing should be requested from a reference labora-
tory when suspected. Second-line drugs include fos-
carnet or cidofovir.
IF HSE IS UNLIKELY, WHEN IS IT SAFE TO STOP
ACICLOVIR?
This is a notoriously difficult decision. If doubt exists,
a full course of aciclovir should be given risking over-
treatment rather than undertreatment. Where clinical
suspicion of HSE is low, it is usually appropriate to
stop aciclovir if
▸ there is a negative CSF HSV PCR and cell count
(<5 cells/mm3) and
▸ normal MRI neuroimaging and
▸ normal EEG and
▸ a full and rapid clinical recovery with normal level of
consciousness or
▸ an alternative diagnosis becomes apparent.
DOES A NEGATIVE LP RULE-OUT HSE?
Aciclovir should not be stopped if the CSF is negative
on PCR for HSV when other features are consistent
with HSE, particularly CSF cell count, MRI findings
or EEG. Note that HSV PCR is a highly sensitive and
specific test (94 and 96%, respectively), except during
the first 24 h of the disease, when as many as 10% of
HSE CSF samples can be falsely negative.13 If suspi-
cion of HSE remains after an initial negative CSF
PCR, a second LP and HSV PCR should be per-
formed before day 4 of treatment.6 In addition, if aci-
clovir treatment is started some days before CSF is
obtained for analysis, the PCR result may be falsely
negative; HSV PCR results are unlikely to be affected
by <48 h of aciclovir therapy and may still be inform-
ative up to a week after therapy is started.14
CAN NEONATAL AND CHILDHOOD HSE RECUR?
Since the introduction of high-dose, prolonged
therapy for neonates and children with proven or sus-
pected HSE, early relapses are less common. Children
presenting with features suggestive of HSV relapse
need repeat cultures of blood and CSF, including CSF
PCR for HSV and autoantibody quantification (see
box 1).
After neonatal HSE, HSV can reactivate months to
years after the initial infection, mostly presenting as
dermal flares, or as an encephalitis as devastating as
the initial illness.15 It is thought that early-life infec-
tion impairs the development of an effective adaptive
immune response,1 but prolonged antiviral prophy-
laxis can prevent recurrence (see below).
Outside the neonatal period, HSE can signify the
presence of underlying immunodeficiencies in the
innate immune system associated with defective virus
recognition, particularly in the TLR3 pathway.16
These children can develop protective adaptive
immune responses. Though there are little data, older
Best practice
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children are not routinely given antiviral prophylaxis
beyond the first 3 months.
Both neonatal and childhood HSE predispose to
subsequent autoimmune encephalitis, with new neuro-
logical symptoms, including aphasia, behavioural
change, choreoathetoid movements and opercular syn-
drome.15 This may require immunomodulatory treat-
ment with neurology advice.
WHAT ABOUT PROPHYLAXIS AFTER HSE?
Prophylaxis with aciclovir has been shown to reduce
HSV relapse.15 While 12 months of antiviral prophy-
laxis is adequate for some children following neonatal
HSE, late central or dermal flares may indicate that
longer-term or even lifelong prophylaxis may be
required. Findings from a small patient series pro-
posed doses of 1340 mg/m2 aciclovir given twice daily
(total daily dose 2680 mg/m2),11 based on CSF pene-
tration data, but a more recent larger placebo-
controlled RCT validated oral aciclovir given at
300 mg/m2 three times daily (900 mg/m2) as adequate
at improving neurodevelopmental outcome.7
Valaciclovir is the prodrug of aciclovir and has
better enteral absorption compared with aciclovir,
producing higher plasma and, most importantly, CSF
concentrations9 and permits a more manageable
dosing regimen. Oral aciclovir is recommended for
neonates and valaciclovir for older children requiring
long-term prophylaxis (table 1).
WHAT ADVICE SHOULD WE GIVE TO PREGNANT
WOMEN WHO HAVE GENITAL HSV IN THE FINAL
WEEKS OF PREGNANCY?
HSV primary infection in the third trimester presents
a significant neonatal risk, and delivery by caesarean
section is advised followed by neonatal screening for
HSV (see below). Babies born vaginally should be
started on intravenous aciclovir at birth.17 Women
with primary HSV infection in the first or second tri-
mester should be prescribed oral or intravenous aci-
clovir, followed by daily suppression with oral
aciclovir from 36 weeks of gestation to reduce the
chances of lesions being present at delivery.
In recurrent HSV infection, the risks are less, but if
active lesions are present at delivery then delivery by
caesarean section may be considered. For vaginally
delivered babies, there are little data to guide initiation
of aciclovir, and there is variable practice. We would
recommend minimising the risk of a devastating
illness by treating all infants born to mothers with
active lesions.17
All babies born to mothers with suspected or proven
active HSV should be screened for HSV by mucosal
(conjunctiva, pharynx, rectum) and skin swabs taken
between 12 and 24 h of age, even after caesarean
section delivery. If HSV is detected, intravenous aciclo-
vir treatment should be continued/initiated.
WHAT ONWARD REFERRAL IS NEEDED?
Where there is a family history of invasive HSV
disease and/or consanguinity, children should be
referred to an immunology centre. Identification of
defects permits family testing, and consideration of
antiviral prophylaxis in HSV-seronegative family
members. Even where this is not the case, childhood
HSE should be discussed with a local tertiary paediat-
ric infectious diseases specialist with access to special-
ist paediatric neurologists.
Children with HSE will require long-term multidis-
ciplinary neurodevelopmental follow-up and possibly
also psychological and educational rehabilitation fol-
lowing what is often a long hospital stay and
Table 1 Treatment of herpes simplex encephalitis (HSE)* (assuming normal renal function and hydration)7 9 10
Birth to 3 months All children >3 months
Intravenous aciclovir
20 mg/kg TDS for at least 21 days
Intravenous aciclovir
3 months to 12 years: 500 mg/m2 TDS for 21 days
Over 12 years: 10 mg/kg TDS for 21 days
Prophylaxis against HSE recurrence
Birth to 3 months Immunocompetent children >3 months Immunocompromised children >3 months
Aciclovir per os (PO)
300 mg/m2 TDS for at least 12 months7
Oral vacaciclovir:
Not recommended—no neonatal data
Aciclovir PO
300 mg/m2 TDS for at least 3 months
OR
1340 mg/m2 BD for at least 3 months11
Valaciclovir PO:
1 month to 12 years
25–40 mg/kg TDS for at least 3 months
Aciclovir PO
300 mg/m2 TDS for at least 12 months
OR
1340 mg/m2 BD for at least 12 months11
Valaciclovir PO:
1 month to 12 years
25–40 mg/kg TDS for at least 12 months
*Dosing information: oral aciclovir is available as suspension at either 400 mg/5 mL (preferred) or 200 mg/5 mL. It is also possible to use reconstituted
dispersible tablets (200 and 400 mg available). For valaciclovir, there is no approved liquid preparation. A palatable, red suspension can be prepared
by pharmacists from crushed tablets (shelf life under refrigeration=28 days).
BD, twice daily; TDS, three times daily.
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convalescence. They also may require treatment for
longer-term complications, including epilepsy, spasti-
city and dystonia. Useful contacts for parents and chil-
dren include charities that offer support to those who
have suffered an acute brain injury, such as the
Encephalitis Society (http://www.encephalitis.info),
Headway and the Child Brain Injury Trust (http://
www.headway.org.uk).
CONCLUSION
HSE is a highly destructive neurotrophic virus; early
diagnosis with early and optimal treatment offers the
best chance to ameliorate the otherwise poor outcome.
In neonates, the outcomes can be particularly severe so
in any febrile neonate presenting with possible sepsis,
neonatal HSE should be considered; where there are
other clues to the diagnosis such as deranged liver func-
tion tests or skin lesions, babies should be commenced
on aciclovir unless an alternative diagnosis is apparent.
All children, irrespective of age, should have CSF
sampling when clinically well enough to tolerate this;
this is usually on admission but should certainly be
early in the disease once stabilised and any coagula-
tion dyscrasias corrected. A repeat diagnostic LP
should be undertaken if there is any doubt about the
original result. Some infection specialists advocate an
end of treatment LP to ensure viral clearance and to
guide the need for long-term prophylaxis.
Once high-dose intravenous aciclovir is started, the
diagnostic work-up must be completed in order to
direct the decision of when to stop antiviral therapy.
This includes evaluation of the clinical, microbio-
logical, radiological and neurophysiological findings.
If significant doubt persists, continuing intravenous
aciclovir for the full 21 days is the only effective way
to minimise risk of undertreatment. However, meticu-
lous history-taking and complete and timely diagnos-
tic work-up will minimise unnecessary treatment.
Risk of HSE recurrence differs greatly between neo-
natal and childhood onset HSE. In neonates, there is
now good evidence that long-term prophylaxis
improves prognosis and reduces the rate of HSE recur-
rence as well as dermal flares. In older children, evi-
dence is emerging that HSE may be due to an isolated
immunodeficiency so as functional and genetic diagnos-
tics continue to expand all children with possible under-
lying immunodeficiency need evaluation by paediatric
infectious disease specialists following HSE.18
Contributors KLD drafted the initial manuscript and drafted
revisions. EM, DP, HL and ML contributed significantly to the
revision of the manuscript and provided pharmacological
information. JH and EM developed the concept for the
manuscript and significantly contributed to the revision and
development of the final manuscript.
Funding KLD is funded by a Wellcome Trust/Imperial Global
Health Fellowship.
Competing interests None.
Provenance and peer review Not commissioned; externally
peer reviewed.
Open Access This is an Open Access article distributed in
accordance with the Creative Commons Attribution Non
Commercial (CC BY-NC 4.0) license, which permits others to
distribute, remix, adapt, build upon this work non-
commercially, and license their derivative works on different
terms, provided the original work is properly cited and the use
is non-commercial. See: http://creativecommons.org/licenses/by-
nc/4.0/
REFERENCES
1 Whitley RJ, Kimberlin DW. Herpes simplex encephalitis:
children and adolescents. Sem Pediatr Infect Dis
2005;16:17–23.
2 Ward KN, Ohrling A, Bryant NJ, et al. Herpes simplex serious
neurological disease in young children: incidence and
long-term outcome. Arch Dis Child 2012;97:162–5.
3 Jurado R, Walker HK. Cerebrospinal fluid. In: Walker HK,
Hall WD, Hurst JW, eds. Clinical methods: the history,
physical, and laboratory examinations. 3rd edn. Boston:
Butterworths, 1990 Chapter 5, there are no page numbers as
this is an online book.
4 Ambrose HE, Granerod J, Clewley JP, et al. Diagnostic strategy
used to establish etiologies of encephalitis in a prospective
cohort of patients in England. J Clin Microbiol
2011;49:3576–83.
5 Long SS, Pool TE, Vodzak J, et al. Herpes simplex virus
infection in young infants during 2 decades of empiric
acyclovir therapy. Pediatr Infect Dis J 2011;30:556–61.
6 Kneen R, Jakka S, Mithyantha R, et al. The management of
infants and children treated with aciclovir for suspected viral
encephalitis. Arch Dis Child 2010;95:100–6.
7 Kimkberlin DW. Acyclovir Dosing in the neonatal period and
beyond. J Paediatr Infect Dis 2013;2:179–82.
8 Kneen R, Michael BD, Menson E, et al. Management of
suspected viral encephalitis in children—Association of British
Neurologists and British Paediatric Allergy, Immunology and
Infection Group national guidelines. J infect 2012;64:449–77.
9 Lim M, Menson E, Tong CY, et al. Use of therapeutic drug
monitoring in the long-term valaciclovir therapy of relapsing
herpes simplex virus encephalitis in children. J Antimicrob
Chemother 2009;64:1340–1.
10 Kimberlin DW, Whitley RJ, Wan W, et al. Oral acyclovir
suppression and neurodevelopment after neonatal herpes. New
Eng J Med 2011;365:1284–92.
11 Rudd C, Rivadeneira ED, Gutman LT. Dosing considerations
for oral acyclovir following neonatal herpes disease. Acta
Paediatrica 1994;83:1237–43.
12 Piret J, Boivin G. Resistance of herpes simplex viruses to
nucleoside analogues: mechanisms, prevalence, and
management. Antimicrob Agents Chemother 2011;55:459–72.
13 Lakeman FD, Whitley RJ. Diagnosis of herpes simplex
encephalitis: application of polymerase chain reaction to
cerebrospinal fluid from brain-biopsied patients and correlation
with disease. National Institute of Allergy and Infectious
Diseases Collaborative Antiviral Study Group. J Infect Dis
1995;171:857–63.
14 Domingues RB, Lakeman FD, Mayo MS, et al. Application of
competitive PCR to cerebrospinal fluid samples from patients
with herpes simplex encephalitis. J Clin Microbiol
1998;36:2229–34.
Best practice
62 Le Doare K, et al. Arch Dis Child Educ Pract Ed 2015;100:58–63. doi:10.1136/archdischild-2014-306321
15 De Tiege X, Rozenberg F, Heron B. The spectrum of herpes
simplex encephalitis in children. Europ J Paediatr Neurol
2008;12:72–81.
16 Banerjee K, R B. Immunopathological aspects of HSV
infection. In: Arvin A, C-F G, Mocarski E, Moore PS,
Roizman B, Whitley R, et al, eds. Human herpesviruses:
biology, therapy, and immunoprophylaxis. Cambridge Edited
by Ann Arvin, Gabriella Campadelli-Fiume, Edward Mocarski,
Patrick S. Moore, Bernard Roizman, Richard Whitley, and
Koichi Yamanishi. Chapter 1: Cambridge University Press,
2007.
17 Royal College of Obstetricians and Gynaecologists.
Management of genital herpes in pregnancy. 2007.
18 Anzivino E, Fioriti D, Mischitelli M, et al. Herpes simplex virus
infection in pregnancy and in neonate: status of art of
epidemiology, diagnosis, therapy and prevention. Virol J 2009;6:40.
Best practice
Le Doare K, et al. Arch Dis Child Educ Pract Ed 2015;100:58–63. doi:10.1136/archdischild-2014-306321 63
